Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.44 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.44 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903280 | 0.81 | TXNRD1 (0.47) | PARP1TXNRD1TXNRD3TXNRD2GABRA1 | |
| SCHEMBL29059881 | 0.76 | ALDH1A1 (0.51) | KMT2AOPRK1PARP1TXNRD1TXNRD3 | |
| SCHEMBL3761599 | 0.75 | KMT2A (0.48) | HSD17B10KMT2AOPRK1PARP1TXNRD1 | |
| SCHEMBL537824 | 0.75 | PARP1 (0.53) | HSD17B10KMT2AOPRK1PARP1TXNRD1 | |
| SCHEMBL30894837 | 0.75 | KMT2A (0.55) | HSD17B10KMT2AOPRK1PARP1TXNRD1 | |
| SCHEMBL4658369 | 0.75 | KMT2A (0.55) | HSD17B10KMT2AOPRK1PARP1TXNRD1 | |
| SCHEMBL6096600 | 0.73 | SMN1; SMN2 (0.43) | PARP1AMY1AACHE | |
| SCHEMBL30950666 | 0.73 | SMN1; SMN2 (0.43) | PARP1AMY1AACHE | |
| SCHEMBL17478740 | 0.73 | KMT2A (0.52) | HSD17B10KMT2AOPRK1PARP1TXNRD1 | |
| SCHEMBL6449426 | 0.73 | KMT2A (0.49) | HSD17B10KMT2AOPRK1PARP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016055982-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS | ACERTA PHARMA B.V. (NL) | 2016-04-14 | — | — | WO | disclosed |
| US-20080045538-A1 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-02-21 | — | — | US | disclosed |
| US-6992089-B2 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE UNIVERSITY OF NEW JERSEY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040102443-A1 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2004-05-27 | — | — | US | disclosed |
| WO-2004014906-A2 | NITRO AND AMINO SUBSTITUTED DIBENZONAPHTHYRIDINES AS TOPOISOMERASE AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045538-A1 | Nitro and amino substituted topoisomerase agents | TOP1, TOP2A, TOP2B | HSD17B10 2684/4885KMT2A 1248/4885OPRK1 2358/4885 |
| US-20040102443-A1 | Nitro and amino substituted topoisomerase agents | TOP1, TOP2A, TOP2B | HSD17B10 2656/4885KMT2A 1259/4885OPRK1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.